Inventage Lab

Inventage Lab Revenue per Share

The Revenue per Share of Inventage Lab (389470.KQ) as of Oct 31, 2026 is 221.34 KRW. In the previous year, Revenue per Share was 177.49 KRW — a change of 24.70% (higher).

Revenue per Share

221.34KRW

YoY

24.70%

Last updated:

Revenue per Share of Inventage Lab is 2025 221.34 KRW. Revenue per Share of Inventage Lab was 2024 177.49 KRW. It decreases by 24.70% higher compared to the previous year.

The Inventage Lab Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2019
0.00 KRW
Jan 1, 2020
64.80 KRW
Jan 1, 2021
226.90 KRW
Jan 1, 2022
445.88 KRW
Jan 1, 2023
77.86 KRW
Jan 1, 2024
177.49 KRW
Jan 1, 2025
221.34 KRW
The Inventage Lab Revenue per Share history
YEARRevenue per ShareYoY
221.34KRW+24.70%
177.49KRW+127.98%
77.86KRW-82.54%
445.88KRW+96.51%
226.90KRW+250.13%
64.80KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Revenue per Share of Inventage Lab is 221.34 KRW in 2025.

Revenue per Share of Inventage Lab changed from 177.49 KRW to 221.34 KRW, representing a 24.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Inventage Lab

All Key Metrics — Inventage Lab